Clinical Trial Update: 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy [Phase 2]

View source ↗

Summary

A Phase II randomized, open-label study evaluating an anti-SLAM monoclonal antibody as maintenance therapy in multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma | Phase 2 | Status: WITHDRAWN